2. Search Result
Search Result
Results for "

obesity-related diabetes

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12425
    DGAT1-IN-1
    2 Publications Verification

    		 Acyltransferase Metabolic Disease
    DGAT1-IN-1 is a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor with a human IC50 of <10 nM and a mouse IC50 of <50 nM. DGAT1-IN-1 is applicable to the research of obesity-related diseases, type 2 diabetes and diabetes-related diseases .
    DGAT1-IN-1
  • HY-173527
    PSSI-51

    		Mitochondrial Metabolism Metabolic Disease
    PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT). PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders .
    PSSI-51
  • HY-P3584A
    (Pro3) GIP, human TFA

    (Pro3) Gastric Inhibitory Peptide, human TFA

    		 Insulin Receptor Metabolic Disease
    (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human TFA
  • HY-P3584
    (Pro3) GIP, human

    (Pro3) Gastric Inhibitory Peptide, human

    		 Insulin Receptor Metabolic Disease
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human
  • HY-19848
    Cevoglitazar

    LBM-642

    		 PPAR Metabolic Disease
    Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
    Cevoglitazar
  • HY-118523
    AL-321

    		Endogenous Metabolite Metabolic Disease
    AL-321 is an insulin sensitizer. AL-321 exhibits significant hypoglycemic and hypolipidemic activities in insulin resistance models. AL-321 can be used in the research of hereditary obesity-related diabetes .
    AL-321
  • HY-182536
    LMPTP IN-2

    		Phosphatase Metabolic Disease
    LMPTP IN-2 is a selective protein tyrosine phosphatase (LMPTP) inhibitor with an IC50 of 0.020 μM. LMPTP IN-2 exerts inhibitory effects through a non-competitive mechanism. LMPTP IN-2 can be used for research on obesity-related insulin resistance and type 2 diabetes .
    LMPTP IN-2
  • HY-182379
    SBI-0802767

    		Phosphatase Metabolic Disease
    SBI-0802767 is an orally active, uncompetitive and highly selective inhibitor of protein tyrosine phosphatase (LMPTP) with an IC50 of 0.239 μM. SBI-0802767 exhibits >1000-fold selectivity over other protein tyrosine phosphatases and enhances insulin signaling in hepatocytes. SBI-0802767 is used in studies of obesity-related type 2 diabetes and insulin resistance .
    SBI-0802767

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: